A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)

Summary

A 12-Week Efficacy Study in participants with Peripheral Arterial Disease. the primary hypothesis is that MK-0736 7 mg administered once daily for 12 weeks will result in a decrease in lower extremity atherosclerotic plaque macrophage content when compared to placebo (an approximate decrease of up to 30% is expected).

Timeline

Start

2007-03-31

Primary completion

2008-08-26

Completion

2008-08-26

Drugs

Indications